Abstract
The global prevalence of dry eye disease (DED) ranges between approximately 5% and 50% and engenders a substantial socioeconomic burden. In the past decade, an unprecedented collaboration between industry and the vision sciences has spawned numerous potential therapeutic agents for DED. Many of these options possess novel mechanisms of action, potentially allowing clinicians to better tailor their treatment of patients suffering from DED. This review covers several specific pipeline drugs, such as lotilaner, perfluorohexyloctane, and cyclosporine A, along with broader drug classes such as reactive aldehyde species inhibitors, keratolytics, and mitochondrial reactive oxidative species scavengers. This review will summarize the promise and efficacy of upcoming dry eye disease treatments through the lens of data from USA-based phase II and phase III clinical trials.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
